Clinical Trial Update: Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating donor-derived HIV-specific T-cells to assess safety, immune responses, and virologic effects in HIV-infected individual…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Donor-derived HIV-specific T-cells (HST)

Snippet

Sponsor: Catherine Bollard | Conditions: HIV-Infected Individuals | Phase 1 | Status: ACTIVE_NOT_RECRUITING